Fresenius Kabi Unveils 2026 Strategy With Focus On Business Not Region

Increased Focus On Biosimilars And Peptides Under New CEO Michael Sen

Fresenius Kabi has revealed a five-year strategic roadmap, driven by its fresh management team, including broadly to increase the injectables specialist’s global competitiveness and advance organizational effectiveness.

Fresenius Kabi
Kabi has grand plans under new CEO Michael Sen • Source: Shutterstock

A strategic plan “going beyond just cost savings” to “better capture existing and new growth opportunities,” has been developed by Fresenius Kabi’s refreshed management team, with the initial step of implementing a “business led rather than regional organization.”

“Vision 2026, that’s the name, is a comprehensive framework to transform Fresenius Kabi for the medium to long-term,” the Fresenius group CEO Stephan Sturm told

More from Earnings

More from Business